Lisa Aschenbrenner

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 284 citations · Full text

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · 2020 · 158 citations · Full text

Acoustic Ejection Mass Spectrometry for High-Throughput Analysis

Hui Zhang, Chang Liu, Wenyi Hua et al. · Analytical Chemistry · 2021 · 96 citations · Full text

Engineering, Analytical Microsystems, Spectrochemical Analysis +19

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

Craig J. McPherson, Lisa Aschenbrenner, Brian M. Lacey et al. · Antimicrobial Agents and Chemotherapy · 2012 · 89 citations · Full text

Immunology, Pharmacotherapy, Antimicrobial Chemotherapy +23